The DNA-binding domain of myelin-gene regulatory factor has been expressed, purified and crystallized. A molecular-replacement solution could not be found using its closest known homologous structure and the selenium-substituted crystals have been generated for Se-SAD phasing and structure determination.
Keywords: myelin-gene regulation, MRF, DNA-binding domain, trimeric transcription factor, X-ray crystallography
Abstract
The myelin sheath, which envelops axons in the vertebrate central nervous system, is crucial for the rapid conduction of action potentials. Myelin-gene regulatory factor (MRF) is a recently identified transcription factor that is required for myelin-sheath formation. Loss of MRF leads to demyelinating diseases and motor learning deficiency. MRF is a membrane-bound transcription factor that undergoes autocleavage from the endoplasmic reticulum membrane. The N-terminus of MRF contains a DNA-binding domain (DBD) that functions as a homotrimer. In this study, the MRF DBD was cloned, purified and crystallized in order to understand the molecular mechanism that regulates the transcription of myelin genes. Selenomethionine was subsequently introduced into the crystals to obtain the phases for the MRF DBD structure. The native and selenomethionine-labelled crystals exhibited diffraction to 2.50 and 2.51 Å resolution, respectively. The crystals belonged to space group P321 and the selenomethionine-labelled crystals had unit-cell parameters a = 104.0, b = 104.0, c = 46.7 Å, α = 90, β = 90, γ = 120°. The calculated Matthews coefficient was 3.04 Å3 Da−1 and the solvent content was 59.5%, indicating the presence of one MRF DBD molecule in the asymmetric unit.
1. Introduction
Myelin, which envelops axons in the vertebrate central nervous system (CNS), is crucial for the rapid and efficient conduction of action potentials in axons. Myelin is a specialized structure that is generated by terminally differentiated oligodendrocytes (OLs) in the CNS (Küspert et al., 2011 ▸; Li et al., 2007 ▸). The production of myelin and the generation of mature OLs involve a fine-tuned process that is regulated by numerous extracellular and intercellular factors (Taveggia et al., 2010 ▸). The loss of myelin causes many severe diseases, such as multiple sclerosis and leukodystrophies. Researchers have recently found that newly generated myelin is required for motor learning in adults (Xiao et al., 2016 ▸; McKenzie et al., 2014 ▸). The myelin-gene regulatory factor (MRF) is required for myelin-gene expression and myelin maintenance (Emery et al., 2009 ▸; Koenning et al., 2012 ▸). The expression of many myelin genes, including MBP, MAG and MOG, is absent when MRF is knocked down. MRF is specifically expressed in post-mitotic OLs and is a membrane-bound transcription factor that is located in the endoplasmic reticulum (ER) membrane (Li et al., 2013 ▸; Bujalka et al., 2013 ▸). After expression, it is autocleaved from the ER membrane, and its N-terminal fragment, which includes a DNA-binding domain (DBD), enters the nucleus to regulate myelin-gene expression. Previous studies showed that the MRF DBD is functional as a homotrimer, which is a rare configuration for a transcription factor (Muth et al., 2016 ▸; Kim et al., 2017 ▸; Li et al., 2013 ▸). To date, structural information on MRF remains lacking, which hinders the complete understanding of this protein and its specific functions. In the present study, we investigated the expression, purification, crystallization and X-ray diffraction of the MRF DBD.
2. Materials and methods
2.1. Macromolecule production
2.1.1. Production and purification of native MRF DBD
The mouse MRF DNA fragment containing the DBD and ICA domains (residues 351–717) was amplified from a full-length gene clone (NP_001028653.1) by standard PCR. The amplified products were then cloned into a modified pRSFDuet-1 expression vector (Novagen) with an N-terminal 6×His tag. The sequence of the final recombined vector RSF_MRF-DBD was validated via DNA sequencing.
The recombinant MRF fragment was obtained by overexpressing RSF_MRF-DBD in Escherichia coli BL21 (DE3) cells (Novagen) that had been induced overnight with 0.5 mM isopropyl β-d-1-thiogalactopyranoside (IPTG) at 18°C. The bacterial cells were harvested by centrifugation at 7000 rev min−1 for 10 min. 5 g of the cell pellet was then resuspended in 50 ml lysis buffer consisting of 50 mM Tris–HCl pH 8.0, 150 mM NaCl. The cells were lysed on ice by ultrasonication and were then centrifuged at 12 000 rev min−1 for 30 min. The clarified supernatant was incubated with nickel Sepharose affinity resin (GE Healthcare) and then washed with lysis buffer. The protein eluted with lysis buffer containing 300 mM imidazole was analyzed by limited proteolytic mapping as follows. Firstly, trypsin (Worthington) was dissolved in a buffer solution consisting of 50 mM Tris–HCl pH 8.0, 20 mM CaCl2 to prepare a 1 mg ml−1 trypsin stock solution. The aliquots were then frozen at −20°C. Trypsin was added to the purified MRF protein in a buffer solution consisting of 50 mM Tris–HCl pH 8.0, 150 mM NaCl. For trypsin limited proteolytic mapping analysis, a stable band was observed with a trypsin:protein ratio of 1:500 000(w:w) at 4°C for 30 min. The eluted protein was subsequently digested with trypsin at 4°C for 30 min. The digestion reaction was terminated by adding a tenfold excess of soybean trypsin inhibitor (Sigma) to the reaction mixture. The stable fragments were further purified by size-exclusion chromatography on a Superdex 75 10/300 GL column (GE Healthcare) that had been pre-equilibrated in a buffer solution consisting of 20 mM Tris–HCl pH 7.4, 150 mM NaCl, 1 mM DTT. The peak fraction was concentrated to 20 mg ml−1 for crystallization (Figs. 1 ▸ b and 1 ▸ c). Macromolecule-production information is summarized in Table 1 ▸.
Figure 1.
Schematic of MRF, trypsin limited proteolytic mapping and purification of the MRF DBD using size-exclusion chromatography. (a) Schematic of the MRF protein showing the fragment expressed and the location of the proteolytic sites (both the autocleavage and trypsin cut sites). (b) Trypsin limited proteolytic mapping was performed and checked by 15% SDS–PAGE. Lane 1 contains the 300 mM imidazole eluate from a nickel-affinity column containing the purified autocleaved product of the MRF DBD. Lane 2 contains trypsinized MRF DBD at a trypsin:protein ratio of 1:500 000(w:w) after gel filtration. Lanes 4–10 contain trypsinized MRF DBD at trypsin:protein ratios of 1:1 000 000, 1:800 000, 1:600 000, 1:500 000, 1:400 000, 1:300 000 and 1:200 000(w:w), respectively. (c) Elution profiles from gel-filtration chromatography of the MRF DBD using Superdex 75 10/300 GL column (GE Healthcare). A calibration curve of proteins with known molecular weights (bovine serum albumin, 66 kDa; chicken ovalbumin, 44 kDa; carbonic anhydrase, 29 kDa) is shown. The molecular weights of these proteins were plotted against their calculated V e/V o and fitted by exponential regression analysis. On the basis of this calculation, the V e/V o of the trypsinized MRF DBD results in a molecular weight of about 24 kDa.
Table 1. Macromolecule-production information.
| Source organism | Mouse |
| DNA source | cDNA |
| Forward primer | CTGCAGGACAGTGACAGCCTCA |
| Reverse primer | CAAACTGGCCTGGGTTAGAGGC |
| Cloning vector | pRSFDuet-1 vector |
| Expression vector | pRSFDuet-1 vector |
| Expression host | E. coli BL21 (DE3) |
| Complete amino-acid sequence of the construct produced† | MGSSHHHHHHSQDPLEVLFQGPEIIKWQPHQQNKWATLYDANYKELPMLTYRVDADKGFNFSVGDDAFVCQKKNHFQVTVYIGMLGEPKYVKTPEGLKPLDCFYLKLHGVKLEALNQSINIEQSQSDRSKRPFNPVTVNLPPEQVTKVTVGRLHFSETTANNMRKKGKPNPDQRYFMLVVALQAHAQNQNYTLAAQISERIIVRASNPGQFESDSDVLWQRAQLPDTVFHHGRVGINTDRPDEALVVHGNVKVMGSLMHPSDLRAKEHVQEVDTTEQLKRISRMRLVHYRYKPEFAASAGIEATAPETGVIAQEVKEILPEAVKDTGDVVFANGKTIENFLVVNKERIFMENVGAVKELCKLTDNLETRIDELERWSHKLAKLRRLDSLKS |
The underlined residues are autocleaved after the protein has been expressed.
2.1.2. Production and purification of selenomethionine-labelled MRF DBD
The RSF_MRF-DBD plasmid (see above) was transformed into E. coli BL21 (DE3) cells. Selenomethionine-labelled MRF DBD was obtained in E. coli BL21 (DE3) cells via methionine-pathway inhibition at 37°C in M9 medium containing 0.4% glucose, 2 mM MgSO4, 0.1 mM CaCl2 and 50 µg l−1 kanamycin (Qoronfleh et al., 1995 ▸; Hendrickson et al., 1990 ▸). The cells were cultured to an OD600 of 0.8. Prior to the addition of IPTG, selenomethionine was supplemented along with leucine, isoleucine and valine at final concentrations of 50 µg l−1. Lysine, threonine and phenylalanine were supplemented to final concentrations of 100 µg l−1. The cells were harvested via centrifugation. Cell pellets were resuspended in lysis buffer (20 mM Tris–HCl pH 8.0, 150 mM NaCl, 1 mM PMSF, 1 mM β-mercaptoethanol). The cells were lysed on ice via ultrasonication and were then centrifuged at 12 000 rev min−1 for 30 min at 4°C. The clarified supernatant was loaded onto nickel Sepharose affinity resin (GE Healthcare) that had been equilibrated in lysis buffer. The column was extensively washed and the target protein was eluted with lysis buffer containing 300 mM imidazole. Fractions containing pure protein were pooled and treated with trypsin at a trypsin:protein ratio of 1:500 000(w:w) at 4°C for 30 min. After the reaction had been terminated with trypsin inhibitor, the reaction mixture was concentrated and then further purified by size-exclusion chromatography using a Superdex 75 10/300 GL column (GE Healthcare) that had been equilibrated in 20 mM Tris–HCl pH 8.0, 150 mM NaCl, 1 mM DTT. The fractions containing pure protein were concentrated to 18 mg ml−1 for crystallization screening.
2.2. Crystallization
Initial crystallization screening was conducted via sitting-drop vapour diffusion. In brief, 0.5 µl purified protein solution was mixed with 0.5 µl reservoir solution at 18°C. Although crystals appeared in PEG 4000, 1 M ammonium formate after 3 d, these crystals did not exhibit diffraction despite extensive optimization. After two weeks, another type of rod-like crystal appeared in buffer consisting of 0.1 M HEPES pH 7.5, 20% PEG 4000, 50 mM magnesium acetate. Selenomethionine-labelled crystals were obtained under similar conditions as for the native crystal. Protein identification was performed on a MALDI TOF-TOF 5800 Analyzer (AB SCIEX, Foster City, California, USA).
2.3. Data collection and processing
The crystals were transferred for 30 s to mother liquor containing 20% glycerol as a cryoprotectant. The crystals were then cooled in liquid nitrogen. Data were collected at the BL17U1 station of the Shanghai Synchrotron Radiation Facility (SSRF; Wang et al., 2015 ▸) and were processed using HKL-2000 and xia2 (Otwinowski & Minor, 1997 ▸; Winter, 2010 ▸; Kabsch, 2010 ▸; Winn et al., 2011 ▸; Evans, 2006 ▸). One data set was collected from a selenomethionine-substituted crystal at the Se peak wavelength (0.9792 Å). The Se sites were identified using SHELX (Sheldrick, 2008 ▸; Schneider & Sheldrick, 2002 ▸). The structure was solved with AutoSol and an initial model was built with AutoBuild. Both programs are part of the PHENIX suite of crystallographic programs (Adams et al., 2010 ▸).
3. Results and discussion
The MRF fragment (351–717) was overexpressed in E. coli and then underwent self-cleavage. The fragment produced a protein with a molecular weight of 30 kDa, compared with the calculated molecular weight of 45 kDa (Fig. 1 ▸ a). The protein was purified using a nickel-affinity column. Initial crystallization trials using this fragment failed to produce crystals. Previous studies showed that this fragment was the product of autoproteolysis by the ICA domain and includes the DBD and the bridge between the DBD and the ICA domain. However, the bridge may not be well structured and possibly hindered crystallization. Limited proteolytic analysis with trypsin confirmed this speculation and generated a stable band (about 24 kDa) for the MRF DBD (Fig. 1 ▸ b). The size-exclusion chromatograph of the protein showed a single peak that corresponded to the monomer (Fig. 1 ▸ c). Crystals appeared in a condition consisting of PEG 4000 and 1 M ammonium formate after 3 d. Unfortunately, few diffraction spots appeared in the low-resolution range for the initial crystals, and the diffraction of crystals obtained under this condition could not be improved by optimizing the pH, the protein concentration or the precipitant concentration. Finally, diffraction-quality crystals and those of the selenomethionine-labelled variant were obtained using a reservoir solution consisting of 0.1 M HEPES pH 7.5, 20% PEG 4000, 50 mM magnesium acetate (Figs. 2 ▸ a and 2 ▸ b). The SDS–PAGE gel showed that the crystals were protein crystals and that they had the same molecular weight as the purified MRF DBD protein (Fig. 2 ▸ c). Western blotting with an anti-His monoclonal antibody showed that the N-terminal His tag is removed by trypsin (Supplementary Fig. S1). The crystals were confirmed to contain MRF protein by a MASCOT search (Supplementary Fig. S2) and had a mass from MALDI–TOF of 24 002 Da, which we believe to correspond to the fragment containing residues 351–559. X-ray diffraction data were collected on beamline BL17U1 of SSRF and were processed at 2.51 Å resolution (Fig. 2 ▸ d). The crystals belonged to space group P321, with unit-cell parameters a = 104.0, b = 104.0, c = 46.7 Å, α = β = 90, γ = 120°. Data-collection and processing statistics are summarized in Table 2 ▸. The rational Matthews coefficient and solvent content of the crystal are 3.04 Å3 Da−1 and 59.5%, respectively, which suggest the presence of one molecule per asymmetric unit (Matthews, 1968 ▸).
Figure 2.
Photographs of MRF DBD crystals, a silver-stained gel of the crystals and an X-ray diffraction image. (a) Optimized native crystals of the MRF DBD obtained in 20% PEG 4000, 50 mM magnesium acetate, 0.1 M HEPES pH 7.5. The approximate dimensions of the crystals are 0.15 × 0.05 × 0.04 mm. (b) Selenomethione-labelled MRF DBD crystals obtained in 20% PEG 4000, 50 mM magnesium acetate, 0.1 M HEPES pH 7.5. The approximate dimensions of the crystals are 0.05 × 0.02 × 0.02 mm. (c) SDS–PAGE gel of the crystals with silver staining. Lane 1 is a control containing the purified MRF DBD protein. Lane 2 contains crystals washed twice with buffer. Lanes 3 and 4 contain the crystal wash buffers. (d) X-ray diffraction image of a selenomethione-labelled MRF DBD crystal.
Table 2. Data collection and processing.
| Selenomethionine-labelled crystal | Native crystal | |
|---|---|---|
| Diffraction source | BL17U1, SSRF | BL17U1, SSRF |
| Wavelength (Å) | 0.9792 | 0.9792 |
| Temperature (K) | 100 | 100 |
| Detector | ADSC Q315r | ADSC Q315r |
| Crystal-to-detector distance (mm) | 250 | 300 |
| Rotation range per image (°) | 1 | 1 |
| Total rotation range (°) | 180 | 180 |
| Exposure time per image (s) | 1 | 1 |
| Space group | P321 | P321 |
| a, b, c (Å) | 104.0, 104.0, 46.7 | 106.8, 106.8, 48.1 |
| α, β, γ (°) | 90, 90, 120 | 90, 90, 120 |
| Mosaicity (°) | 0.34 | 0.25 |
| Resolution range (Å) | 34.75–2.51 (2.55–2.51) | 48.11–2.50 (2.54–2.50) |
| Total No. of reflections | 107970 (4391) | 119004 (5444) |
| No. of unique reflections | 10187 (481) | 11154 (552) |
| Completeness (%) | 99.8 (97.4) | 99.7 (97.4) |
| Multiplicity | 10.6 (9.1) | 10.7 (9.9) |
| 〈I/σ(I)〉 | 18.1 (2.0) | 16.4 (2.3) |
| R meas | 0.100 (0.983) | 0.093 (0.956) |
| Overall B factor from Wilson plot (Å2) | 49.7 | 49.7 |
The MRF DBD is conserved in evolution, and its closest homologue is the yeast sporulation-specific transcription factor Ndt80. A molecular-replacement solution could not be found using Ndt80 (PDB entry 1m6u; Montano et al., 2002 ▸) as a model. Structure analysis showed that Ndt80 is an Ig-fold transcription factor with an extra helix and a larger loop compared with other similar transcription factors (Lamoureux et al., 2002 ▸). However, the size of MRF is closer to those of the general Ig-fold transcription factors. This difference may be the reason why a molecular-replacement solution could not be found. To determine the phases of the MRF DBD structure, single-wavelength anomalous diffraction data were collected from a selenomethionine-labelled crystal. Four Se sites were found in the asymmetric unit (of the expected four sites per molecule) using SHELX. The structure was solved with AutoSol and an initial model was built with AutoBuild. Analysis of the crystal packing revealed that the MRF DBD forms a trimer with a crystallographic threefold axis (Fig. 3 ▸). The detailed structural analysis and biochemical studies of the MRF DBD will be published elsewhere. The high-resolution structure of the MRF DBD may provide insights into the mechanism of trimeric transcription factors.
Figure 3.
Electron density of Se atoms as anomalous signal in an MRF DBD trimer. The red density represents an anomalous map contoured at 5.0σ. The green lines indicate the unit cell.
Supplementary Material
Supplementary Figures S1 and S2.. DOI: 10.1107/S2053230X17007828/rl5144sup1.pdf
References
- Adams, P. D. et al. (2010). Acta Cryst. D66, 213–221.
- Bujalka, H., Koenning, M., Jackson, S., Perreau, V. M., Pope, B., Hay, C. M., Mitew, S., Hill, A. F., Lu, Q. R., Wegner, M., Srinivasan, R., Svaren, J., Willingham, M., Barres, B. A. & Emery, B. (2013). PLoS Biol. 11, e1001625. [DOI] [PMC free article] [PubMed]
- Emery, B., Agalliu, D., Cahoy, J. D., Watkins, T. A., Dugas, J. C., Mulinyawe, S. B., Ibrahim, A., Ligon, K. L., Rowitch, D. H. & Barres, B. A. (2009). Cell, 138, 172–185. [DOI] [PMC free article] [PubMed]
- Evans, P. (2006). Acta Cryst. D62, 72–82. [DOI] [PubMed]
- Hendrickson, W. A., Horton, J. R. & LeMaster, D. M. (1990). EMBO J. 9, 1665–1672. [DOI] [PMC free article] [PubMed]
- Kabsch, W. (2010). Acta Cryst. D66, 125–132. [DOI] [PMC free article] [PubMed]
- Kim, D., Choi, J.-O., Fan, C., Shearer, R. S., Sharif, M., Busch, P. & Park, Y. (2017). Nucleic Acids Res. 45, 5112–5125. [DOI] [PMC free article] [PubMed]
- Koenning, M., Jackson, S., Hay, C. M., Faux, C., Kilpatrick, T. J., Willingham, M. & Emery, B. (2012). J. Neurosci. 32, 12528–12542. [DOI] [PMC free article] [PubMed]
- Küspert, M., Hammer, A., Bösl, M. R. & Wegner, M. (2011). Nucleic Acids Res. 39, 1280–1293. [DOI] [PMC free article] [PubMed]
- Lamoureux, J. S., Stuart, D., Tsang, R., Wu, C. & Glover, J. N. M. (2002). EMBO J. 21, 5721–5732. [DOI] [PMC free article] [PubMed]
- Li, H., Lu, Y., Smith, H. K. & Richardson, W. D. (2007). J. Neurosci. 27, 14375–14382. [DOI] [PMC free article] [PubMed]
- Li, Z., Park, Y. & Marcotte, E. M. (2013). PLoS Biol. 11, e1001624. [DOI] [PMC free article] [PubMed]
- Matthews, B. W. (1968). J. Mol. Biol. 33, 491–497. [DOI] [PubMed]
- McKenzie, I. A., Ohayon, D., Li, H., Paes de Faria, J., Emery, B., Tohyama, K. & Richardson, W. D. (2014). Science, 346, 318–322. [DOI] [PMC free article] [PubMed]
- Montano, S. P., Cote, M. L., Fingerman, I., Pierce, M., Vershon, A. K. & Georgiadis, M. M. (2002). Proc. Natl Acad. Sci. USA, 99, 14041–14046. [DOI] [PMC free article] [PubMed]
- Muth, K. N., Piefke, S., Weider, M., Sock, E., Hermans-Borgmeyer, I., Wegner, M. & Küspert, M. (2016). Glia, 64, 2120–2132. [DOI] [PubMed]
- Otwinowski, Z. & Minor, W. (1997). Methods Enzymol. 276, 307–326. [DOI] [PubMed]
- Qoronfleh, M. W., Ho, T. F., Brake, P. G., Banks, T. M., Pulvino, T. A., Wahl, R. C., Eshraghi, J., Chowdhury, S. K., Ciccarelli, R. B. & Jones, B. N. (1995). J. Biotechnol. 39, 119–128. [DOI] [PubMed]
- Schneider, T. R. & Sheldrick, G. M. (2002). Acta Cryst. D58, 1772–1779. [DOI] [PubMed]
- Sheldrick, G. M. (2008). Acta Cryst. A64, 112–122. [DOI] [PubMed]
- Taveggia, C., Feltri, M. L. & Wrabetz, L. (2010). Nature Rev. Neurol. 6, 276–287. [DOI] [PMC free article] [PubMed]
- Wang, Q. S. et al. (2015). Nucl. Sci. Tech. 26, 010102.
- Winn, M. D. et al. (2011). Acta Cryst. D67, 235–242.
- Winter, G. (2010). J. Appl. Cryst. 43, 186–190.
- Xiao, L., Ohayon, D., McKenzie, I. A., Sinclair-Wilson, A., Wright, J. L., Fudge, A. D., Emery, B., Li, H. & Richardson, W. D. (2016). Nature Neurosci. 19, 1210–1217. [DOI] [PMC free article] [PubMed]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Supplementary Figures S1 and S2.. DOI: 10.1107/S2053230X17007828/rl5144sup1.pdf



